Detailed Narrative
Overall Strong Financial Performance
India Glycols reported a quarter of record performance, with both Q3 and 9M FY26 achieving highest-ever revenue and EBITDA. For 9M FY26, net revenue grew 11% to INR 3,235 crores, and EBITDA increased 29% to INR 487 crores, resulting in a 15.0% margin. Q3 FY26 alone saw net revenue growth of 13.0% and EBITDA growth of 36.1%, with margins reaching 16.0%. PAT for 9M FY26 also saw a healthy increase of 23% to INR 206 crores.
Strategic Focus on Bio-based and Premiumization
The company's growth strategy is aligned with evolving macro trends, emphasizing bio-based ingredients and value realization across its consumer and potable spirits segments. This involves a dual approach of innovation and cost efficiency, coupled with connecting to end consumers through lifestyle products. A key focus is on premiumization and superior innovation to build broader partnerships and enhance product offerings.
Potable Spirits Segment Drives Growth and Expansion
The Potable Spirits segment demonstrated strong performance, contributing significantly to overall growth. For 9M FY26, net revenue grew 17% year-on-year to INR 1,025 crores, with volumes increasing 5% to 23.7 million cases. The company is actively expanding its premium and luxury portfolio, strengthening partnerships with brands like Amrut and Bacardi, and launching new state-specific single malts. Distribution is being enhanced, including entry into 34 CSD depots pan-India.
Chemicals Business Restructuring and New Product Pipeline
The Bio-based Specialty Chemicals and Performance Chemicals segment showed outstanding EBITDA growth of 68% in Q3 and 26% in 9M. This improvement is attributed to structured actions, including discontinuing low-margin businesses and optimizing operational philosophy. The company has commenced commercial sales of bio-based amines to L'Oreal and is developing a strong pipeline of over 30 new products, targeting segments like crop protection, personal care, and oilfield.
Biofuels Segment Performance and Policy Dependence
The Biofuels segment experienced robust growth, with Q3 revenue up 45.2% and EBIT up 273.2%, and 9M revenue up 51.2% and EBIT up 108.5%. Margins improved from 3.3% to 8.4% in Q3. This growth is largely driven by India's ethanol blending program, which has reached 20%. While blending beyond 20% is under consideration by NITI Aayog, it presents challenges related to vehicle modifications and infrastructure, making future margin expansion range-bound and policy-dependent.
Proactive Debt Management and Cost Optimization
India Glycols made significant strides in debt reduction, decreasing it by INR 582 crores. This included utilizing INR 467 crores from a preferential allotment and an additional INR 116 crores from internal accruals in Q3. The company plans to repay another INR 75-100 crores in Q4, aiming for a term loan of approximately INR 1,100 crores by March 31, 2026. Furthermore, INR 130 crores of high-cost debt were swapped, leading to interest cost savings of 125-150 basis points.
Ennature Biopharma Challenges and Recovery Initiatives
The Ennature Biopharma segment faced a challenging period, with EBIT margins at 4.1% in Q3 and 2.9% in 9M FY26, primarily due to cost pressures on feedstocks and volatility in Western markets. To address this, the company is focusing on stabilizing raw material supply, restarting nicotine sales, and launching new branded nutraceuticals like Gingeren and Asparagine. Efforts are also underway to build standardized ingredients and improve certifications to strengthen global market presence.